Journal Description
Neurology International
Neurology International
is an international, peer-reviewed, open access journal which provides an advanced forum for studies related to all aspects of neurology and neuroscience, published bimonthly online by MDPI (from Volume 12 issue 3 - 2020).
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.
- Journal Rank: JCR - Q2 (Clinical Neurology)
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.1 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
- Journal Clusters-Neurosciences: Brain Sciences, Neurology International, NeuroSci, Clinical and Translational Neuroscience, Neuroglia, Psychiatry International, Clocks & Sleep and Journal of Dementia and Alzheimer's Disease.
Impact Factor:
3.2 (2023);
5-Year Impact Factor:
2.6 (2023)
Latest Articles
Evolution of Cognitive Disorders in Patients with Mild Cognitive Impairment (MCI) After Ischemic Stroke: Secondary Data Analysis from the Improved Health Care in Neurology and Psychiatry—Longer Life (IHCNP) Study
Neurol. Int. 2024, 16(6), 1626-1635; https://doi.org/10.3390/neurolint16060118 - 21 Nov 2024
Abstract
Background: The Improved Health Care in Neurology and Psychiatry—Longer Life (IHCNP) study was an 18-month prospective, observational, non-interventional research study focused on patients with mild cognitive impairment (MCI) following ischemic stroke. Objectives: Our secondary analysis of the IHCNP data aimed to document the
[...] Read more.
Background: The Improved Health Care in Neurology and Psychiatry—Longer Life (IHCNP) study was an 18-month prospective, observational, non-interventional research study focused on patients with mild cognitive impairment (MCI) following ischemic stroke. Objectives: Our secondary analysis of the IHCNP data aimed to document the progression of MCI in this patient group. Methods: A total of 100 patients from Romania were recruited, all of whom underwent cognitive assessments using the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Rey Auditory Verbal Learning Test (RAVLT). Clinical evaluations were also conducted as part of the study. Baseline cognitive scores were recorded, and subsequent follow-ups documented cognitive changes over time. Results: At baseline, cognitive scores indicated mild impairment, with averages of MMSE 25.41, MoCA 23.27, and RAVLT 33.63. By the end of the study, patients exhibited a significant cognitive decline, with MMSE scores dropping by 8.7%, MoCA by 10.0%, and RAVLT by 29.5% (p < 0.0001 for all measures), reflecting the progressive nature of MCI post-stroke. Conclusions: These findings highlight the importance of early diagnosis and intervention to mitigate cognitive decline in post-stroke patients. The study underscores the need for ongoing cognitive monitoring to improve patient outcomes and manage MCI progression effectively.
Full article
(This article belongs to the Special Issue Emerging Issues in Vascular Cognitive Impairment)
►
Show Figures
Open AccessReview
Macamides as Potential Therapeutic Agents in Neurological Disorders
by
Karin J. Vera-López, Gonzalo Davila-Del-Carpio and Rita Nieto-Montesinos
Neurol. Int. 2024, 16(6), 1611-1625; https://doi.org/10.3390/neurolint16060117 - 21 Nov 2024
Abstract
►▼
Show Figures
Therapeutic treatment of nervous system disorders has represented one of the significant challenges in medicine for the past several decades. Technological and medical advances have made it possible to recognize different neurological disorders, which has led to more precise identification of potential therapeutic
[...] Read more.
Therapeutic treatment of nervous system disorders has represented one of the significant challenges in medicine for the past several decades. Technological and medical advances have made it possible to recognize different neurological disorders, which has led to more precise identification of potential therapeutic targets, in turn leading to research into developing drugs aimed at these disorders. In this sense, recent years have seen an increase in exploration of the therapeutic effects of various metabolites extracted from Maca (Lepidium meyenii), a plant native to the central alpine region of Peru. Among the most important secondary metabolites contained in this plant are macamides, molecules derived from N-benzylamides of long-chain fatty acids. Macamides have been proposed as active drugs to treat some neurological disorders. Their excellent human tolerance and low toxicity along with neuroprotective, immune-enhancing, and and antioxidant properties make them ideal for exploration as therapeutic agents. In this review, we have compiled information from various studies on macamides, along with theories about the metabolic pathways on which they act.
Full article
Figure 1
Open AccessArticle
Sensitization and Habituation of Hyper-Excitation to Constant Presentation of Pattern-Glare Stimuli
by
Thomas Jefferis, Cihan Dogan, Claire E. Miller, Maria Karathanou, Austyn Tempesta, Andrew J. Schofield and Howard Bowman
Neurol. Int. 2024, 16(6), 1585-1610; https://doi.org/10.3390/neurolint16060116 - 21 Nov 2024
Abstract
Background/Objectives: Pattern glare, associated with cortical hyperexcitability, induces visual distortions and discomfort, particularly in individuals susceptible to migraines or epilepsy. While previous research has primarily focused on transient EEG responses to patterned stimuli, this study aims to investigate how continuous presentation of pattern-glare
[...] Read more.
Background/Objectives: Pattern glare, associated with cortical hyperexcitability, induces visual distortions and discomfort, particularly in individuals susceptible to migraines or epilepsy. While previous research has primarily focused on transient EEG responses to patterned stimuli, this study aims to investigate how continuous presentation of pattern-glare stimuli affects neural adaptation over both fine (seconds) and coarse (entire experiment) temporal scales. Methods: EEG recordings were obtained from 40 healthy participants exposed to horizontal square-wave gratings at three spatial frequencies presented continuously for three seconds each across multiple trials. Participants’ susceptibility to visual stress, headaches, and discomfort was assessed using questionnaires before and during the experiment. The experiment employed a two-by-two design to evaluate habituation (exponentially decreasing response) and sensitisation (exponentially increasing response) effects at two different time granularities. Mass univariate analysis with cluster-based permutation tests was conducted to identify significant brain response changes during the period of constant stimulation, which we call the DC-shift period. Results: Significant effects were observed during the DC-shift period, indicating sustained hyper-excitation to the medium-pattern glare stimulus. In particular, the mean/intercept analysis revealed a consistent positive-going response to the medium stimulus throughout the DC-shift period, suggesting continued neural engagement. Participants reporting higher discomfort exhibited sensitisation at fine temporal granularity and habituation at coarser temporal granularity. These effects were predominantly localised to the right posterior scalp regions. Conclusions: The study demonstrates that individuals sensitive to pattern-glare stimuli exhibit dynamic neural adaptation characterised by short-term sensitisation and long-term habituation. These findings enhance the understanding of cortical hyperexcitability mechanisms and may inform future interventions for visual-stress-related conditions, such as migraines and epilepsy. Further research is needed to explore the underlying neural processes and validate these effects in clinical populations.
Full article
(This article belongs to the Special Issue Migraines and Beyond: Advances in the Pathogenesis and Treatment of Chronic Headache Disorders, Second Edition)
►▼
Show Figures
Figure 1
Open AccessReview
Mindfulness-Based Interventions and the Hypothalamic–Pituitary–Adrenal Axis: A Systematic Review
by
Hernando Vargas-Uricoechea, Alejandro Castellanos-Pinedo, Karen Urrego-Noguera, Hernando D. Vargas-Sierra, María V. Pinzón-Fernández, Ernesto Barceló-Martínez and Andrés F. Ramírez-Giraldo
Neurol. Int. 2024, 16(6), 1552-1584; https://doi.org/10.3390/neurolint16060115 - 20 Nov 2024
Abstract
►▼
Show Figures
Background: Numerous studies have evaluated the effect that mindfulness-based interventions (MBIs) have on multiple health outcomes. For its part, stress is a natural response to environmental disturbances and within the associated metabolic responses, alterations in cortisol levels and their measurement in different tissues
[...] Read more.
Background: Numerous studies have evaluated the effect that mindfulness-based interventions (MBIs) have on multiple health outcomes. For its part, stress is a natural response to environmental disturbances and within the associated metabolic responses, alterations in cortisol levels and their measurement in different tissues are a way to determine the stress state of an individual. Therefore, it has been proposed that MBIs can modify cortisol levels. Methods and results: The objective of this systematic review was to analyze and summarize the different studies that have evaluated the effect of MBIs on cortisol levels. The following databases were consulted: MEDLINE, AMED, CINAHL, Web of Science, Science Direct, PsycINFO, SocINDEX, PubMed, the Cochrane Library and Scopus. The search terms “mindfulness”, “mindfulness-based interventions” and “cortisol” were used (and the search was limited to studies from January 1990 to May 2024). In order to reduce selection bias, each article was scrutinized using the JBI Critical Appraisal Checklist independently by two authors. We included those studies with specified intervention groups with at least one control group and excluded duplicate studies or those in which the intervention or control group was not adequately specified. Significant changes in cortisol following MBIs were found in 25 studies, while 10 found no changes. The small sample size, lack of randomization, blinding, and probable confounding and interaction variables stand out in these studies. Conclusion: MBIs have biological plausibility as a means of explaining a positive effect on cortisol levels; however, the weakness of the studies and the absence of robust designs makes it difficult to establish a causal association between both variables. Registration number: INPLASY2024110017.
Full article
Figure 1
Open AccessArticle
Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis
by
Gisela M. Vaitaitis and David H. Wagner, Jr.
Neurol. Int. 2024, 16(6), 1540-1551; https://doi.org/10.3390/neurolint16060114 - 20 Nov 2024
Abstract
►▼
Show Figures
Background/Objectives: One of the first-line disease-modifying treatments of multiple sclerosis (MS) is Glatiramer Acetate (GA), which requires daily or three-times-weekly subcutaneous injections. Disease progression, while slowed, still occurs with time. Increasing the impact of the treatment while decreasing the frequency of injections would
[...] Read more.
Background/Objectives: One of the first-line disease-modifying treatments of multiple sclerosis (MS) is Glatiramer Acetate (GA), which requires daily or three-times-weekly subcutaneous injections. Disease progression, while slowed, still occurs with time. Increasing the impact of the treatment while decreasing the frequency of injections would be ideal. The mechanism of action of GA remains undefined. We developed an alternate approach, KGYY6, whose mechanism of action targets the CD40 receptor with promising results in an Experimental Autoimmune Encephalomyelitis (EAE) model. Methods: GA and a CD40-targeting peptide, KGYY6, were formulated as slow-release particles used to treat EAE in C57BL/6 mice. Results: Compared to liquid formulations, the particle formulations vastly improved drug efficacy in both cases, which would be advantageous in treating MS. GA is a combination of randomly generated peptides, in the size range of 5000–9000 Da, using the amino acids E, A, Y, and K. This approach introduces batch differences that impacts efficacy, a persistent problem with GA. KGYY6 is generated in a controlled process and has a motif, K-YY, which could be generated when manufacturing GA. When testing two different lots of GA or KGYY6, the latter performed equally well across lots, while GA did not. Conclusions: Slow-release formulations of both GA and KGYY6 vastly improve the efficacy of both, and KGYY6 is more consistent in efficacy across different lots.
Full article
Graphical abstract
Open AccessArticle
Risk of Stroke or Heart Attack in Mild Cognitive Impairment and Subjective Cognitive Impairment
by
Michele Lauriola, Luigi Esposito, Grazia D’Onofrio, Filomena Ciccone, Annamaria la Torre, Filomena Addante, Annagrazia Cocomazzi, Leandro Cascavilla, Olga Ariano, Gaetano Serviddio and Antonio Greco
Neurol. Int. 2024, 16(6), 1528-1539; https://doi.org/10.3390/neurolint16060113 - 19 Nov 2024
Abstract
Background: The study aimed to identify Mild Cognitive Impairment (MCI) as an alert clinical manifestation of increased probability of major acute vascular events (MVEs), such as Ischemic Stroke and heart attack. Methods: In a longitudinal study, 181 (M = 81, F = 100;
[...] Read more.
Background: The study aimed to identify Mild Cognitive Impairment (MCI) as an alert clinical manifestation of increased probability of major acute vascular events (MVEs), such as Ischemic Stroke and heart attack. Methods: In a longitudinal study, 181 (M = 81, F = 100; mean age of 75.8 ± 8.69 years) patients were enrolled and divided into three groups based on diagnosis: Subjective Cognitive Impairment (SCI), amnestic MCI Single Domain (aMCI-SD), and amnestic MCI More Domain (aMCI-MD). Clinical assessment and the presence of vascular risk factors were collected. Results: The distribution of MVEs showed a higher incidence in the first two years of follow-up of 7.4% in SCI, 12.17% in aMCI-SD, and 8.57% in aMCI-MD. Acute Myocardial Infarction showed a major incidence in one year of follow-up (41%) and in two years of follow-up (29%). Also, Ischemic Stroke showed a major incidence in one year of follow-up (30%) and in two years of follow-up (40%). A statistically significant difference in the progression to dementia was shown (SCI 3.75%; aMCI-SD 10.43%; aMCI-MD 37%; p-value < 0.001). Conclusions: MCI is considered an expression of the systemic activation of mechanisms of endothelial damage, representing a diagnosis predictive of increased risk of MVEs.
Full article
(This article belongs to the Special Issue Emerging Issues in Vascular Cognitive Impairment)
►▼
Show Figures
Figure 1
Open AccessReview
Mucuna pruriens, a Possible Treatment for Depressive Disorders
by
Alfonso Mata-Bermudez, Araceli Diaz-Ruiz, Luis Ricardo Silva-García, Eduardo Manuel Gines-Francisco, Roxana Noriega-Navarro, Camilo Rios, Héctor Alonso Romero-Sánchez, Diego Arroyo, Abraham Landa and Luz Navarro
Neurol. Int. 2024, 16(6), 1509-1527; https://doi.org/10.3390/neurolint16060112 - 16 Nov 2024
Abstract
►▼
Show Figures
Depression is a mental disorder that depicts a wide variety of symptoms, including mood and cognitive alterations, as well as recurrent thoughts of death or suicide. It could become the second leading cause of premature death or disability worldwide. Treatments with conventional antidepressants
[...] Read more.
Depression is a mental disorder that depicts a wide variety of symptoms, including mood and cognitive alterations, as well as recurrent thoughts of death or suicide. It could become the second leading cause of premature death or disability worldwide. Treatments with conventional antidepressants have several limitations in terms of effectiveness, side effects, and high costs. Therefore, medicinal plants such as Mucuna pruriens are potent candidates for treating depressive disorders. This review shows a compendium of evidence supporting the antidepressant effect of the Mucuna pruriens plant in diverse animal models. This includes the mechanisms of action underlying the antidepressant activity of the treatment concerning dopamine, serotonin, norepinephrine, reactive oxygen species, nitric oxide, cortisol, and inflammation. Clinical trials are needed to study the efficacy and safety of Mucuna pruriens for depression.
Full article
Figure 1
Open AccessSystematic Review
The Neurological Impact of Leprosy: Manifestations and Treatment Approaches
by
Andrea Calderone, Maria Catena Aloisi, Carmela Casella, Salvatore Fiannacca, Bruno Cosenza, Angelo Quartarone and Rocco Salvatore Calabrò
Neurol. Int. 2024, 16(6), 1492-1508; https://doi.org/10.3390/neurolint16060111 - 16 Nov 2024
Abstract
►▼
Show Figures
Background and Objectives: Leprosy primarily affects peripheral nerves, leading to significant neurological complications such as polyneuritis, mononeurosis, and autonomic dysfunction, which contribute to severe disabilities and impaired quality of life for patients. This scoping review aims to investigate the neurological manifestations and main
[...] Read more.
Background and Objectives: Leprosy primarily affects peripheral nerves, leading to significant neurological complications such as polyneuritis, mononeurosis, and autonomic dysfunction, which contribute to severe disabilities and impaired quality of life for patients. This scoping review aims to investigate the neurological manifestations and main treatments of leprosy patients. Materials and Methods: Studies were identified from an online search of PubMed, Web of Science, Cochrane Library, Embase, and Scopus databases. This review has been registered on OSF (n) PQBYH. Results: Neurological complications of leprosy, such as neuropathy and paralysis, necessitate accurate diagnosis and treatment, as immunological reactions can exacerbate nerve damage. Various studies highlight the effectiveness of personalized therapies, such as corticosteroids, multi-drug therapy (MDT), and surgical interventions, in improving symptoms and neurological function in leprosy patients. Conclusions: Managing neurological complications of leprosy necessitates careful diagnosis and treatment, as many patients experience unresolved peripheral neuropathy despite multidrug therapy. Future research should focus on improving diagnostic tools, exploring the link between neuropathic pain and psychological issues, and developing effective vaccines and treatments to enhance patient outcomes.
Full article
Figure 1
Open AccessArticle
Wavelet-Detected Changes in Nocturnal Brain Electrical Activity in Patients with Non-Motor Disorders Indicative of Parkinson’s Disease
by
Anastasiya E. Runnova, Maksim O. Zhuravlev, Anton R. Kiselev, Ruzanna R. Parsamyan, Margarita A. Simonyan and Oxana M. Drapkina
Neurol. Int. 2024, 16(6), 1481-1491; https://doi.org/10.3390/neurolint16060110 - 16 Nov 2024
Abstract
►▼
Show Figures
Background/Objectives—Parkinson’s disease (PD) is the second most common neurodegenerative disorder caused by the destruction of neurons in the substantia nigra of the brain. Clinical diagnosis of this disease, based on monitoring motor symptoms, often leads to a delayed start of PD therapy and
[...] Read more.
Background/Objectives—Parkinson’s disease (PD) is the second most common neurodegenerative disorder caused by the destruction of neurons in the substantia nigra of the brain. Clinical diagnosis of this disease, based on monitoring motor symptoms, often leads to a delayed start of PD therapy and control, where over 60% of dopaminergic nerve cells are damaged in the brain substantia nigra. The search for simple and stable characteristics of EEG recordings is a promising direction in the development of methods for diagnosing PD and methods for diagnosing the preclinical stage of PD development. Methods—42 subjects participated in work, of which 4 female/10 male patients were included in the group of patients with non-motor disorders, belonging to the risk group for developing PD (median age: 62 years, height: 164 cm, weight: 70 kg, pulse: 70, BPsys and BPdia: 143 and 80)/(median age: 68 years, height: 170 cm, weight: 73.9 kg, pulse: 75, BPsys and BPdia: 143 and 82). The first control group of healthy participants included 6 women (median age: 33 years, height: 161 cm, weight: 66 kg, pulse: 80, BPsys and BPdia: 110 and 80)/8 men (median age: 36.3 years, height: 175 cm, weight: 69 kg, pulse: 78, BPsys and BPdia: 120 and 85). The second control group of healthy participants included 8 women (median age: 74 years, height: 164 cm, weight: 70 kg, pulse: 70, BPsys and BPdia: 145 and 82)/6 men (median age: 51 years, height: 172 cm, weight: 72.5 kg, pulse: 74, BPsys and BPdia: 142 and 80). Wavelet oscillatory pattern estimation is performed on patients’ nocturnal sleep recordings without separating them into sleep stages. Results—Amplitude characteristics of oscillatory activity in patients without motor disorders and the prodromal PD stage are significantly reduced both in terms of changes in the number of patterns and in terms of their duration. This pattern is especially pronounced for high-frequency activity, in frequency ranges close to 40 Hz. Conclusions—The success of the analysis of the electrical activity of the brain, performed over the entire duration of the night recording, makes it promising to further use during daytime monitoring the concept of oscillatory wavelet patterns in patients with non-motor disorders, belonging to the risk group for developing PD. The daytime monitoring system can become the basis for developing screening tests to detect neurodegenerative diseases as part of routine medical examinations.
Full article
Figure 1
Open AccessArticle
Headaches in Healthcare Workers: A Prospective Study of Precipitating and Maintenance Variables and Their Relationship with Burnout as a Post-COVID Syndrome
by
Fernanda Gil-Almagro, Francisco Javier Carmona-Monge, Fernando José García-Hedrera and Cecilia Peñacoba-Puente
Neurol. Int. 2024, 16(6), 1464-1480; https://doi.org/10.3390/neurolint16060109 - 14 Nov 2024
Abstract
Background: Headaches are a common symptom in healthcare workers (HCWs), mainly associated with high levels of stress. Different research has studied their incidence during the COVID-19 pandemic, most of them with correlational designs, and at the beginning of the pandemic and focused on
[...] Read more.
Background: Headaches are a common symptom in healthcare workers (HCWs), mainly associated with high levels of stress. Different research has studied their incidence during the COVID-19 pandemic, most of them with correlational designs, and at the beginning of the pandemic and focused on the associated occupational variables. Aims: (1) To analyze the incidence of headaches in HCWs at the beginning of the COVID-19 pandemic and their maintenance six months later. (2) To explore the risk factors associated with their onset and maintenance, including sociodemographic, occupational, emotional symptomatology, and personality variables. (3) To propose a model to explain the chronification of stress in burnout, including the moderating role of chronic headaches. Methods: A prospective study (n = 259 HCWs) at three points in time during the COVID-19 pandemic, from the alarm state phase (T1: May–June 2020) to the post-pandemic stage (T3: April–July 2022), including an intermediate measure six months after T1 (T2). Descriptive analyses, Pearson’s chi-square, Student’s t, logistic regressions, and moderated mediation models were conducted using the Process package for SPSS. In addition to headaches, socio-demographic, occupational, emotional symptomatology, and personality variables were included. Results: At T1 the prevalence of headaches was 69.9%. At T2 the prevalence was 73.7%. Of these, 59.5% are T1–T2 sustained headaches. Headaches at T1 were associated with age (p = 0.010) (younger HCWs), professional category (p = 0.049) (nurses), service (p = 0.023) (ICU, COVID hospitalization), non-availability of PPE (p = 0.010), additional COVID-19 symptomatology (p < 0.001), and concern for contagion of family members (p < 0.001) (higher scores). In addition, HCWs with headaches had higher levels of stress (p = 0.001), anxiety (p = 0.001), depression (p = 0.041), and sleep disorders (p < 0.001). A subsequent logistic regression analysis showed that of the above variables, the presence of additional COVID-19 symptoms (p < 0.001) and depression (p = 0.010) were the predictor variables. With regard to the maintenance of headaches (T1–T2), anxiety (p = 0.035), stress (p = 0.001), and cognitive fusion (p = 0.013) were found to be the significant variables. The tested model proposes anxiety (T1) as antecedent, cognitive fusion (T2) as mediator, burnout (T3) as consequent, and chronic headaches (yes/no) as the moderating variable between anxiety and burnout (model 5). The model is significant (F = 19.84, p < 0.001) and contributes to the explanation of 36% of the variance of burnout. The relationships in the model are all statistically significant, and specifically chronic headaches contribute to a 6-fold increase in the likelihood of burnout. Conclusions: The present research differentiates between precipitating and maintenance factors of headaches in HCWs. The former, more studied in previous research, are usually related to sociodemographic and occupational variables and levels of anxiety and stress. Maintenance factors, scarcely explored, are related to the maintenance of emotional symptomatology and the inability to manage intrusive thoughts (i.e., cognitive fusion). Of particular interest is that the presence of chronic headaches itself is capable of producing burnout as a post-COVID syndrome.
Full article
(This article belongs to the Special Issue Migraines and Beyond: Advances in the Pathogenesis and Treatment of Chronic Headache Disorders, Second Edition)
►▼
Show Figures
Figure 1
Open AccessReview
Application of Muscle Synergies for Gait Rehabilitation After Stroke: Implications for Future Research
by
Jaehyuk Lee, Kimyung Kim, Youngchae Cho and Hyeongdong Kim
Neurol. Int. 2024, 16(6), 1451-1463; https://doi.org/10.3390/neurolint16060108 - 13 Nov 2024
Abstract
Background/Objective: Muscle synergy analysis based on machine learning has significantly advanced our understanding of the mechanisms underlying the central nervous system motor control of gait and has identified abnormal gait synergies in stroke patients through various analytical approaches. However, discrepancies in experimental conditions
[...] Read more.
Background/Objective: Muscle synergy analysis based on machine learning has significantly advanced our understanding of the mechanisms underlying the central nervous system motor control of gait and has identified abnormal gait synergies in stroke patients through various analytical approaches. However, discrepancies in experimental conditions and computational methods have limited the clinical application of these findings. This review seeks to integrate the results of existing studies on the features of muscle synergies in stroke-related gait abnormalities and provide clinical and research insights into gait rehabilitation. Methods: A systematic search of Web of Science, PubMed, and Scopus was conducted, yielding 10 full-text articles for inclusion. Results: By comprehensively reviewing the consistencies and differences in the study outcomes, we emphasize the need to segment the gait cycle into specific phases (e.g., weight acceptance, push-off, foot clearance, and leg deceleration) during the treatment process of gait rehabilitation and to develop rehabilitation protocols aimed at restoring normal synergy patterns in each gait phase and fractionating reduced synergies. Conclusions: Future research should focus on validating these protocols to improve clinical outcomes and introducing indicators to assess abnormalities in the temporal features of muscle synergies.
Full article
(This article belongs to the Special Issue Treatment Strategy and Mechanism of Acute Ischemic Stroke)
►▼
Show Figures
Figure 1
Open AccessSystematic Review
Survival After Shunt Therapy in Normal-Pressure Hydrocephalus: A Meta-Analysis of 1614 Patients
by
Johannes Wach, Agi Güresir, Erdem Güresir and Martin Vychopen
Neurol. Int. 2024, 16(6), 1438-1450; https://doi.org/10.3390/neurolint16060107 - 11 Nov 2024
Abstract
Background: Ventriculoperitoneal (VP) shunt therapy is a crucial intervention for normal-pressure hydrocephalus (NPH). This meta-analysis delves into survival time and the impact of baseline symptom burden on survival after VP shunt therapy for NPH, employing reconstructed pooled survival curves and a one-stage meta-analysis.
[...] Read more.
Background: Ventriculoperitoneal (VP) shunt therapy is a crucial intervention for normal-pressure hydrocephalus (NPH). This meta-analysis delves into survival time and the impact of baseline symptom burden on survival after VP shunt therapy for NPH, employing reconstructed pooled survival curves and a one-stage meta-analysis. Methods: IPD regarding overall survival (OS) were acquired from published Kaplan–Meier charts, utilizing the R package IPDfromKM in R (Version 4.3.1, the R Foundation for Statistical Computing). Reconstructed Kaplan–Meier charts were then generated from the pooled IPD data. Both one-stage and two-stage meta-analyses were executed, with hazard ratios (HRs) employed as metrics to evaluate effectiveness. Results: From the initial screening of 216 records, five articles encompassing 1614 patients met the eligibility criteria for inclusion. In two of the five included studies, overall survival was stratified by gait score (1–4 vs. ≥4) in 1043 patients, continence score (1–3 vs. ≥4) in 1022 patients, and mRS (0–2 vs. ≥3) in 956 patients. Patients with good gait demonstrated a mean survival of 8.24 years, while those with poor gait had a mean survival of 6.19 years (log-rank test: p < 0.001). The HR for gait was 2.25 (95% CI: 1.81–2.81, p < 0.001). Continence score stratification revealed a significant difference in survival time (log-rank test: p < 0.001), with an HR of 1.66 (95% CI: 1.33–2.06, p < 0.001). Similarly, mRS stratification demonstrated a significant survival difference (log-rank test: p < 0.001), with an HR of 2.21 (95% CI: 1. 74–2.80, p < 0.001). The reconstructed survival curves for all NPH patients treated with VP shunt therapy, pooling data from five studies, revealed a median survival time of 8.82 years (95% CI: 8.23–9.40). Survival rates at 1, 3, 5, 7, 9, 11, and 13 years were 95.7%, 83.8%, 70.5%, 59.5%, 48.7%, 35.8%, and 25.4%, respectively. Comparison with a general control population showed an HR of 1.79 (95% CI: 1.62–1.98, p < 0.001). Conclusions: This comprehensive meta-analysis underscores the influence of baseline symptom burden on survival after VP shunt therapy in NPH. Therapy in the early stages for those without significant comorbidities may enhance survival.
Full article
(This article belongs to the Collection Advances in Neurodegenerative Diseases)
►▼
Show Figures
Figure 1
Open AccessReview
Utilization of Single-Pulse Transcranial-Evoked Potentials in Neurological and Psychiatric Clinical Practice: A Narrative Review
by
Hilla Fogel, Noa Zifman and Mark Hallett
Neurol. Int. 2024, 16(6), 1421-1437; https://doi.org/10.3390/neurolint16060106 - 11 Nov 2024
Abstract
►▼
Show Figures
Background: The utility of single-pulse TMS (transcranial magnetic stimulation)-evoked EEG (electroencephalograph) potentials (TEPs) has been extensively studied in the past three decades. TEPs have been shown to provide insights into features of cortical excitability and connectivity, reflecting mechanisms of excitatory/inhibitory balance, in various
[...] Read more.
Background: The utility of single-pulse TMS (transcranial magnetic stimulation)-evoked EEG (electroencephalograph) potentials (TEPs) has been extensively studied in the past three decades. TEPs have been shown to provide insights into features of cortical excitability and connectivity, reflecting mechanisms of excitatory/inhibitory balance, in various neurological and psychiatric conditions. In the present study, we sought to review and summarize the most studied neurological and psychiatric clinical indications utilizing single-pulse TEP and describe its promise as an informative novel tool for the evaluation of brain physiology. Methods: A thorough search of PubMed, Embase, and Google Scholar for original research utilizing single-pulse TMS-EEG and the measurement of TEP was conducted. Our review focused on the indications and outcomes most clinically relevant, commonly studied, and well-supported scientifically. Results: We included a total of 55 publications and summarized them by clinical application. We categorized these publications into seven sub-sections: healthy aging, Alzheimer’s disease (AD), disorders of consciousness (DOCs), stroke rehabilitation and recovery, major depressive disorder (MDD), Parkinson’s disease (PD), as well as prediction and monitoring of treatment response. Conclusions: TEP is a useful measurement of mechanisms underlying neuronal networks. It may be utilized in several clinical applications. Its most prominent uses include monitoring of consciousness levels in DOCs, monitoring and prediction of treatment response in MDD, and diagnosis of AD. Additional applications including the monitoring of stroke rehabilitation and recovery, as well as a diagnostic aid for PD, have also shown encouraging results but require further evidence from randomized controlled trials (RCTs).
Full article
Figure 1
Open AccessArticle
Evaluating the Usability of a Remote Ischemic Conditioning Device for Pre-Hospital Stroke Management: Insights from Paramedic Simulations
by
Bogna Anna Drozdowska, Kaden Lam, Cody Doolan, Efrem Violato and Aravind Ganesh
Neurol. Int. 2024, 16(6), 1405-1420; https://doi.org/10.3390/neurolint16060105 - 9 Nov 2024
Abstract
Background/Objectives: In acute stroke, often-prolonged hospital transport times present an opportunity for early interventions to salvage brain tissue. Remote ischemic conditioning (RIC), where brief cycles of ischemia–reperfusion in a limb are induced to protect the brain, is a promising treatment for this setting.
[...] Read more.
Background/Objectives: In acute stroke, often-prolonged hospital transport times present an opportunity for early interventions to salvage brain tissue. Remote ischemic conditioning (RIC), where brief cycles of ischemia–reperfusion in a limb are induced to protect the brain, is a promising treatment for this setting. We assessed the usability of a novel RIC system in a simulated emergency response scenario. Methods: Paramedics were asked to use the RIC device in an emergency stroke care and ambulance transport simulation, overseen by a confederate. Feedback on device use was collected through questionnaires, including the System Usability Scale (SUS) and the NASA Task Load Index (NASA-TLX), and a semi-structured interview. Questionnaire responses were summarized using descriptive statistics; interview transcripts were analyzed thematically. Results: Nine paramedics (including the confederate) participated, with a mean of 10.0 ± 10.3 years of professional experience. Questionnaire responses indicated high device usability (mean SUS score: 85.3 ± 12.9 out of 100) and low task-related demands, effort, and frustration (mean NASA-TLX domain scores: ≤3.9 out of 20). Seven paramedics stated they would use the device in daily practice. They expressed concerns related to display screen clarity, interference with standard procedures, cable management, device fragility, and patient discomfort. Suggested improvements included adding indicators of device performance and refining the cuff design. Conclusions: While the device was considered easy to use, paramedics also identified important areas of improvement. With a small, localized study sample, our findings are primarily applicable to the refinement of the RICovery system for use in future clinical trials in the same healthcare setting. However, feedback on the importance of mitigating potential interference of newly introduced procedures with those already established, robustness of equipment, and effective paramedic–patient communication may also help inform the design of other pre-hospital interventions.
Full article
(This article belongs to the Special Issue Treatment Strategy and Mechanism of Acute Ischemic Stroke)
►▼
Show Figures
Figure 1
Open AccessSystematic Review
Effectiveness and Feasibility of Blood Flow Restriction Training for People with Multiple Sclerosis: A Systematic Review
by
Aitor Blázquez-Fernández, Selena Marcos-Antón and Roberto Cano-de-la-Cuerda
Neurol. Int. 2024, 16(6), 1385-1404; https://doi.org/10.3390/neurolint16060104 - 7 Nov 2024
Abstract
Background: Multiple sclerosis (MS) is an immune-mediated inflammatory disease that primarily targets the myelin of axons. Extremities are frequently affected, resulting in a negative impact on both activities of daily living (ADL) and quality of life. In recent years, there has been increasing
[...] Read more.
Background: Multiple sclerosis (MS) is an immune-mediated inflammatory disease that primarily targets the myelin of axons. Extremities are frequently affected, resulting in a negative impact on both activities of daily living (ADL) and quality of life. In recent years, there has been increasing interest in the potential benefits of exercise and blood flow restriction training (BFRT) programs as a therapeutic tool in people with neurological disorders. The aim of the present systematic review was to know the clinical effects of BFRT programs in people with MS. Methods: A systematically comprehensive literature search was conducted and registered in PROSPERO prior to its execution under the reference number CRD42024588963. The following data sources were used: Pubmed, Scopus, Web of Science (WOS) and the Cochrane Library. The following data were extracted from the papers: study design, sample, interventions, dosage, outcome measures and results. To assess the methodological quality of the papers included, the Quality Index of Downs and Black was used. Additionally, the articles were classified according to the levels of evidence and grades of recommendation for diagnosis studies established by the Oxford Center for Evidence-Based Medicine. Also, the Cochrane Handbook for Systematic Reviews of Interventions was used by two independent reviewers to assess risk of bias, assessing the six different domains. Results: Seven articles with a total of 71 participants were included in the review. Of the seven articles, five papers studied the effectiveness of BFRT combined with strengthening exercises and two papers studied the effect of BFRT combined with aerobic exercise. Of the five articles that analyzed BFRT combined with strengthening exercises, only two presented a control group. Both performed a low-load resistance training in combination with BFRT with four series, 30/15/15/15 repetitions and a rest of 1 min between the series and 3 min between the exercises. The control groups to which they were compared performed a high intensity strengthening exercise protocol which had the same exercises, sets, rests and duration of the protocol as the experimental groups. For those two papers which investigated the effects of BFRT combined with aerobic training, exercise was performed in two sessions per week for a period of 8 and 6 weeks, respectively. In both studies, the experimental protocol began with a warm-up phase and ended with a cool-down phase, and there were differences in cuff management. All these investigations found positive effects in the interventions that combined exercise with BFRT. The characteristics, outcome measures, effects of the interventions and the assessment of the methodological quality of the included studies and risk of bias are shown in the tables. Conclusions: BFRT in people with MS appears to be effective and safe for people with MS. BFRT might show positive clinical effects on strength, hypertrophy and balance outcomes. Nevertheless, future research should be conducted with better methodological quality to ensure the potential benefits of BFRT in people with MS since the studies analyzed present a high risk of bias and methodological limitations.
Full article
(This article belongs to the Topic Neurorehabilitation in Movement Disorders and Neurodegenerative Diseases)
►▼
Show Figures
Figure 1
Open AccessArticle
Differential Effects of Extracellular Vesicles from Two Different Glioblastomas on Normal Human Brain Cells
by
Mary Wang, Arin N. Graner, Bryne Knowles, Charlotte McRae, Anthony Fringuello, Petr Paucek, Michael Gavrilovic, McKenna Redwine, Caleb Hanson, Christina Coughlan, Stacey Grimaldo-Garcia, Brooke Metzger, Vince Bolus, Timothy J. Kopper, Marie Smith, Wenbo Zhou, Morgan Lenz, Aviva Abosch, Steven Ojemann, Kevin O. Lillehei, Xiaoli Yu and Michael W. Graneradd
Show full author list
remove
Hide full author list
Neurol. Int. 2024, 16(6), 1355-1384; https://doi.org/10.3390/neurolint16060103 - 6 Nov 2024
Abstract
Background/Objectives: Glioblastomas (GBMs) are dreadful brain tumors with abysmal survival outcomes. GBM extracellular vesicles (EVs) dramatically affect normal brain cells (largely astrocytes) constituting the tumor microenvironment (TME). We asked if EVs from different GBM patient-derived spheroid lines would differentially alter recipient brain cell
[...] Read more.
Background/Objectives: Glioblastomas (GBMs) are dreadful brain tumors with abysmal survival outcomes. GBM extracellular vesicles (EVs) dramatically affect normal brain cells (largely astrocytes) constituting the tumor microenvironment (TME). We asked if EVs from different GBM patient-derived spheroid lines would differentially alter recipient brain cell phenotypes. This turned out to be the case, with the net outcome of treatment with GBM EVs nonetheless converging on increased tumorigenicity. Methods: GBM spheroids and brain slices were derived from neurosurgical patient tissues following informed consent. Astrocytes were commercially obtained. EVs were isolated from conditioned culture media by ultrafiltration, concentration, and ultracentrifugation. EVs were characterized by nanoparticle tracking analysis, electron microscopy, biochemical markers, and proteomics. Astrocytes/brain tissues were treated with GBM EVs before downstream analyses. Results: EVs from different GBMs induced brain cells to alter secretomes with pro-inflammatory or TME-modifying (proteolytic) effects. Astrocyte responses ranged from anti-viral gene/protein expression and cytokine release to altered extracellular signal-regulated protein kinase (ERK1/2) signaling pathways, and conditioned media from EV-treated cells increased GBM cell proliferation. Conclusions: Astrocytes/brain slices treated with different GBM EVs underwent non-identical changes in various omics readouts and other assays, indicating “personalized” tumor-specific GBM EV effects on the TME. This raises concern regarding reliance on “model” systems as a sole basis for translational direction. Nonetheless, net downstream impacts from differential cellular and TME effects still led to increased tumorigenic capacities for the different GBMs.
Full article
(This article belongs to the Special Issue Glioblastoma: Mechanics of Development, Progression and New Surgical and Clinical Management)
►▼
Show Figures
Graphical abstract
Open AccessReview
Painful Legs and Moving Toes Syndrome: Case Report and Review
by
Mihael Tsalta-Mladenov, Vladina Dimitrova and Silva Andonova
Neurol. Int. 2024, 16(6), 1343-1354; https://doi.org/10.3390/neurolint16060102 - 4 Nov 2024
Abstract
Introduction: Painful legs and moving toes (PLMT) syndrome is a rare movement disorder characterized by defuse lower limb neuropathic pain and spontaneous abnormal, involuntary toe movements. Objective: The objective was to present a rare case of PLMT syndrome with a triggering area in
[...] Read more.
Introduction: Painful legs and moving toes (PLMT) syndrome is a rare movement disorder characterized by defuse lower limb neuropathic pain and spontaneous abnormal, involuntary toe movements. Objective: The objective was to present a rare case of PLMT syndrome with a triggering area in an adult patient due to multilevel discogenic pathology, to make a thorough review of this disorder and to provide a practical approach to its management. Case presentation: A 59-years-old male was admitted to the neurology ward with symptoms of defuse pain in the lower-back and the right leg accompanied by involuntary movements for the right toes intensified by tactile stimulation in the right upper thigh. Magnetic resonance imaging (MRI) revealed a multilevel discogenic pathology of the lumbar and cervical spine, with myelopathy at C5-C7 level. A medication with Pregabalin 300 mg/daily significantly improved both the abnormal toe movements and the leg pain. The clinical effect was constant during the 90-day follow-up without any adverse effects. Conclusion: Painful legs and moving toes (PLMT) is a condition that greatly affects the quality of life of patients, but which still remains less known by clinicians. Spontaneous resolution is rare, and oral medications are the first-line treatment. Pregabalin is a safe and effective treatment option for PLMT that should be considered early for the management of this condition. Other medication interventions, such as botulinum toxin injections, spinal blockade, or non-pharmacological treatment options like spinal cord stimulation, and surgical decompressions, are also recommended when the conservative treatment is ineffective in well-selected patients.
Full article
(This article belongs to the Special Issue New Insights into Movement Disorders)
►▼
Show Figures
Figure 1
Open AccessArticle
Effects of Respiratory Training on Pulmonary Function, Cough, and Functional Independence in Patients with Amyotrophic Lateral Sclerosis
by
Eleonora Magni, Anja Hochsprung, Rocío Cáceres-Matos, Manuel Pabón-Carrasco, Beatriz Heredia-Camacho, Ignacio Solís-Marcos and Carlos Luque-Moreno
Neurol. Int. 2024, 16(6), 1332-1342; https://doi.org/10.3390/neurolint16060101 - 1 Nov 2024
Abstract
Background: Respiratory complications in patients with amyotrophic lateral sclerosis (ALS), due to the involvement of respiratory muscles, are the leading cause of death, and respiratory physiotherapy (RP) focuses on addressing these complications. Objectives: The objective was to evaluate the effectiveness of an RP
[...] Read more.
Background: Respiratory complications in patients with amyotrophic lateral sclerosis (ALS), due to the involvement of respiratory muscles, are the leading cause of death, and respiratory physiotherapy (RP) focuses on addressing these complications. Objectives: The objective was to evaluate the effectiveness of an RP intervention that combines the four specific techniques (inspiratory muscle training, lung volume recruitment, manually assisted coughing, and diaphragmatic breathing training) in patients with ALS. Methods: A quasi-experimental study was carried out, and a specific RP programme was implemented in 15 patients with ALS (12 sessions, 30 min/session, one session/week, duration of three months), based on directed ventilation techniques, lung volume recruitment, manually assisted coughing, and the use of incentive spirometry and a cough assist device, along with a daily home exercise programme. Respiratory functions were assessed (pre- and post-intervention, with follow-up at three months) using Forced Vital Capacity (FVC) and Peak Expiratory Cough Flow (PECF); functionality was assessed using the Revised ALS Functional Rating Scale (ALSFRS-R) and the Modified Barthel Index by Granger. Results: FVC experienced an increase after three months of the intervention initiation (p = 0.30), which was not sustained at the three-month follow-up after the intervention ended. All other variables remained practically constant after treatment, with their values decreasing at follow-up. Conclusion: A specific RP intervention could have beneficial effects on respiratory functions, potentially preventing pulmonary infections and hospitalisations in patients with ALS. It may improve FVC and help stabilize the patient's functional decline. Considering the progressive and degenerative nature of the disease, this finding could support the usefulness of these techniques in maintaining respiratory function.
Full article
(This article belongs to the Topic Neurorehabilitation in Movement Disorders and Neurodegenerative Diseases)
►▼
Show Figures
Figure 1
Open AccessReview
The Role of Neuropeptide Y in the Pathogenesis of Alzheimer’s Disease: Diagnostic Significance and Neuroprotective Functions
by
Ksenia Shapovalova, Yana Zorkina, Olga Abramova, Alisa Andryushchenko, Vladimir Chekhonin and Georgy Kostyuk
Neurol. Int. 2024, 16(6), 1318-1331; https://doi.org/10.3390/neurolint16060100 - 1 Nov 2024
Abstract
Background. Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases. It has been suggested that the factors that cause pathologic changes and lead to the development of AD may also include changes in certain neuropeptides. The implication of the neuropeptide
[...] Read more.
Background. Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases. It has been suggested that the factors that cause pathologic changes and lead to the development of AD may also include changes in certain neuropeptides. The implication of the neuropeptide (NPY) in the pathogenesis of AD and its potential therapeutic role is possible due to the following properties: involvement in adult neurogenesis, regulatory effects on the immune system, the inhibition of potential-dependent Ca2+ channels, and the reduction in glutamate excitotoxicity. The aim of our review was to summarize recent data on the role of NPY in AD development and to explore its potential as a biomarker and a possible therapeutic target. Materials and methods. We performed a systematic review of studies, for which we search using the keywords “Alzheimer’s disease and neuropeptide Y”, “Alzheimer’s disease and NPY”, “AD and NPY”, “Neuropeptide Y and Neurodegenerative disease”. Nineteen articles were included in the review. Results. The NPY levels in cerebrospinal fluid and plasma have been found to be reduced or unchanged in AD patients; however, these findings need to be confirmed in more recent studies. Data obtained in transgenic animal models support the role of NPY in AD pathogenesis. The neuroprotective effects of NPY have been demonstrated in vitro and in vivo in AD models. Conclusion. The findings may open new possibilities for using NPY as a diagnostic marker to detect AD at earlier stages of the disease or as a potential therapeutic target due to its neuroprotective properties.
Full article
(This article belongs to the Collection Advances in Neurodegenerative Diseases)
►▼
Show Figures
Figure 1
Open AccessArticle
Cyproheptadine Treatment in Children and Adolescents with Migraine: A Retrospective Study in Japan
by
Hideki Shimomura, Sachi Tokunaga, Eisuke Terasaki, Naoko Taniguchi, Yohei Taniguchi, Saeka Yoshitake, Yuki Terakita, Kenji Inoue, Masumi Okuda, Takeo Kato and Yasuhiro Takeshima
Neurol. Int. 2024, 16(6), 1308-1317; https://doi.org/10.3390/neurolint16060099 - 30 Oct 2024
Abstract
Objective: Evidence on prophylactic drugs for pediatric migraine is limited, especially when comorbid conditions contribute to treatment resistance. This study evaluated the efficacy of cyproheptadine in children with migraine and explored the impact of comorbid neurodevelopmental disorders and orthostatic intolerance (OI). Methods: We
[...] Read more.
Objective: Evidence on prophylactic drugs for pediatric migraine is limited, especially when comorbid conditions contribute to treatment resistance. This study evaluated the efficacy of cyproheptadine in children with migraine and explored the impact of comorbid neurodevelopmental disorders and orthostatic intolerance (OI). Methods: We retrospectively analyzed pediatric migraine patients treated with cyproheptadine. Efficacy was assessed based on the reduction in headache frequency, with responders defined as patients experiencing at least a 50% reduction in headache episodes. Fisher’s exact test analyzed the relationship between efficacy and comorbid conditions or treatment sequence. Multiple logistic regression was performed to identify factors associated with adverse events. Results: In total, 155 children (71 males, 84 females) aged 3–15 years were included. Comorbid neurodevelopmental disorders and OI were present in 27 (17.4%) and 22 (14.2%) patients, respectively. Efficacy was evaluated in 148 patients, with 68.9% classified as responders. Patients with comorbid conditions showed lower efficacy. Responders required a lower dose of cyproheptadine (p = 0.039). Multiple logistic regression identified headache frequency, cyproheptadine dose, and comorbid OI and neurodevelopmental disorders as factors influencing treatment efficacy. Conclusions: Cyproheptadine is effective in treating pediatric migraine, though patients with neurodevelopmental disorders and OI demonstrated reduced efficacy.
Full article
(This article belongs to the Special Issue Migraines and Beyond: Advances in the Pathogenesis and Treatment of Chronic Headache Disorders, Second Edition)
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Biomedicines, IJMS, JCM, Medicina, Neurology International
Advances in Exercise-Induced Neurogenesis, Neuronal and Functional Adaptations in Neurorehabilitation
Topic Editors: Carlos Bernal-Utrera, Cleofas Rodriguez-Blanco, Maria Livia Carrascal MorenoDeadline: 22 December 2024
Topic in
Antioxidants, Biomolecules, JCDD, Metabolites, Neurology International, Pharmaceutics
Tissue-Specific, Disease-Signatured Macrophages in Control of Redox and Antioxidation in Metabolic Diseases
Topic Editors: Xiangwei Xiao, Yingmei Feng, Zhiyong LeiDeadline: 5 July 2025
Topic in
Brain Sciences, Neurology International, NeuroSci
Research Advances in Psychiatric Diseases: Focusing on the Prediction of Suicide
Topic Editors: Maria Skibińska, Monika Wiłkość-Dębczyńska, Przemysław ZakowiczDeadline: 15 September 2025
Topic in
Biomolecules, Cancers, Diseases, Neurology International, Biomedicines
Brain Cancer Stem Cells and Their Microenvironment
Topic Editors: Maria Patrizia Stoppelli, Luca Colucci-D'Amato, Francesca BianchiniDeadline: 31 December 2025
Conferences
Special Issues
Special Issue in
Neurology International
Glial Changes in Psychiatric Disorders
Guest Editor: Shingo MiyataDeadline: 30 November 2024
Special Issue in
Neurology International
New Insights into Movement Disorders
Guest Editor: Kensuke IkenakaDeadline: 30 November 2024
Special Issue in
Neurology International
Emerging Issues in Vascular Cognitive Impairment
Guest Editors: Dragos Catalin Jianu, Dafin Fior Muresanu, Jean Claude SadikDeadline: 31 December 2024
Special Issue in
Neurology International
Biomarker Research in Neuromuscular Diseases
Guest Editor: Endre PálDeadline: 28 February 2025
Topical Collections
Topical Collection in
Neurology International
Brain Health Initiative: Advocacy in Global Neurology
Collection Editors: Tissa Wijeratne, Leila Karimi, Dilani Wijeratne
Topical Collection in
Neurology International
Advances in Neurodegenerative Diseases
Collection Editors: Vasileios Siokas, Efthimios Dardiotis
Topical Collection in
Neurology International
Biomarkers in Stroke Prognosis
Collection Editors: Dimitrios Tsiptsios, Konstantinos Vadikolias
Topical Collection in
Neurology International
Exclusive Papers from the Editorial Board Members (EBMs) of Neurology InternationalCollection Editor: Junji Yamauchi